Skip to main content
SpringerLink
Log in

Mammakarzinom

  • Chapter
Die Gynäkologie

  • 135 Accesses

Zusammenfassung

Das Mammakarzinom galt bis in die 60er Jahre des letzten Jahrhunderts als eine lokoregionäre Erkrankung, die in der Brust entsteht und primär in die Lymphbahnen der Axilla, des Mediastinums und parasternal entlang der A. mammaria interna metastasiert. Diese sog. Halsted-Theorie (Halsted 1894) hat die Behandlung des Mammakarzinoms während 70 Jahren bestimmt, indem immer radikalere Operationen mit dem Ziel der Heilung zur Anwendung kamen (➔ Tabelle 32.1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ahr A, Kahn T, Solbach C, Seiter T, Strelhardt K, Holtrich H, Kaufmann M (2002) Identification of high risk breast cancer patients by gene expression profiling. Lancet 359: 131–133

    Article  PubMed  Google Scholar 

  • Batson OV (1967) The vertebral system of veins as a means for cancer dissemination. Prog Clin Cancer 3: 1–18

    PubMed  CAS  Google Scholar 

  • Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment, with illustrative cases. Lancet II (104): 162

    Article  Google Scholar 

  • Black MM, Speer FD (1957) Nuclear structure in cancer tissues. Surg Gynecol Obstet ío 5: 97–105

    Google Scholar 

  • Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. A study of 1049 cases, of which 359 have been followed 15 years. Br J Cancer 11: 359–377

    Article  PubMed  CAS  Google Scholar 

  • Boyd NF, Martin LJ, Noffel M, Lockwood GA, Trichler DL (1993) A meta-analysis of studies of dietary fat and breast cancer risk. Br J Cancer 68 (3): 627–636

    Article  PubMed  CAS  Google Scholar 

  • Boyle P, Zheng T (2001) Environmental features influencing the epidemiology of breast cancer. The Breast 10 (S3): 1–8

    Google Scholar 

  • Braun S, Pantel K, Muller P et al. (2000). Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342 (8): 525–533

    Article  PubMed  CAS  Google Scholar 

  • Carter CL, Jones DY, Schatzkin A, Brinton LA (1989) A prospective study of reproductive, familial and socioeconomic risk factors for breast cancer using NHANES I data. Public Health Rep 104 (1): 45–50

    PubMed  CAS  Google Scholar 

  • De Larco JE, Reynolds R, Carlberg K, Engle C, Todaro GJ (1980) Sarcoma growth factor from mouse sarcoma virus-transformed cells. Purification by binding and elution from epidermal growth factor receptor-rich cells. J Biol Chem 255 (8): 3685–3690

    PubMed  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (9114): 1451–1467

    Article  Google Scholar 

  • Fisher B (1979) Sounding board. Breast cancer management: alternatives to radical mastectomy. N Engl J Med 301 (6): 326–328

    Article  PubMed  CAS  Google Scholar 

  • Fisher B, Slack NH, Bross ID (1969) Cancer of the breast: size of neoplasm and prognosis. Cancer 24 (5): 1071–1080

    Article  PubMed  CAS  Google Scholar 

  • Fisher B, Slack N, Katrych D, Wolmark N (1975) Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140 (4): 528–534

    PubMed  CAS  Google Scholar 

  • Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19 (18): 3817–3827

    PubMed  CAS  Google Scholar 

  • Haagensen CD (1986) Diseases of the Breast, 3rd ed. Philadelphia: Saunders

    Google Scholar 

  • Halsted W (1894) The results of operations for cure of cancer of the breast performed at John Hopkins Hospital. Johns Hopkins Hosp Bull 4: 497–507

    Google Scholar 

  • Harris JR, Hellman S (1996) Natural History of breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Philadelphia: Lippincott-Raven Publishers

    Google Scholar 

  • Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW (1999) Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220–1226

    Article  PubMed  CAS  Google Scholar 

  • Jordan VC (2001) Oestrogen receptors, growth factors and the control of breast cancer. The Breast 10 (S3): 27–35

    Google Scholar 

  • Kaufmann M, Jonat W, von Minckwitz G (20oí) Aktuelle Empfehlungen zur Therapie primärer Mammakarzinome. Dt Ärztebl 98 (33): A2121–A2123

    Google Scholar 

  • Key TJ, Allen NE (2001) Nutrition and breast cancer. The Breast 10 (S 3): 9–13

    Google Scholar 

  • Muller A, Homey B, Soto H et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (6824): 50-56

    Article  PubMed  CAS  Google Scholar 

  • Paget S (1889) The distribution of secondary growth in cancer of the breast. Lancet I: 571–573

    Google Scholar 

  • Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocrine-related Cancer 8: 11–31

    Article  PubMed  CAS  Google Scholar 

  • Revillion F, Bonneterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791–808

    Article  PubMed  CAS  Google Scholar 

  • Rozan S, Vincent-Salomon A, Zafrani B et al. (1998) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79: 27–33

    Article  PubMed  CAS  Google Scholar 

  • Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Ferno M, Parwaresch R (1999) Correlation between p53, cerbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathology 187: 207–216

    Article  CAS  Google Scholar 

  • Scharl A, Costa SD, von Minckwitz G, Kaufmann M (1998) Neuere Entwicklungen und operative Möglichkeiten bei der Behandlung von Brustkrebs. Forschung Frankfurt 4: 54–66

    Google Scholar 

  • Tetu B, Brisson J, Plante V, Bernard P (1998) p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 823–830)

    Google Scholar 

  • Thiersch C (1865) Der Epithelialkrebs namentlich der Haut. Leipzig: Engelmann

    Google Scholar 

  • Thor AD, Berry DA, Budman DR et al. (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 9o: 1346–1360

    Google Scholar 

  • Thor AD, Liu S, Moore DH 2nd, Edgerton SM (1999) Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Onco117: 470–477

    Google Scholar 

  • Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy. Cancer 41: 1170–1178

    Article  PubMed  CAS  Google Scholar 

  • Varmus HE, Vogt PK, Bishop JM (1973) Integration of deoxyribonucleic acid specific for Rous sarcoma virus after infection of permissive and nonpermissive hosts. Proc Natl Acad Sci USA 70 (11): 3067–3071

    Article  PubMed  CAS  Google Scholar 

  • Veronesi U, Rilke F, Luini A et al. (1987) Distribution of axillary lymph node metastases by level of invasion: An analysis of 539 cases. Cancer 59: 682–687

    Article  PubMed  CAS  Google Scholar 

  • Veronesi U, Saccozzi R, Del Vecchio M et al. (1981) Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 305 (1): 6–11

    Article  PubMed  CAS  Google Scholar 

  • von Minckwitz G, Sinn HP, Raab G, Blohmer JU, Graf E, Kaufmann M (2000) Evaluation of predictive factors in a randomized trial of preoperative dose-intensified adriamycin-docetaxel +I- tamoxifen in primary operable breast cancer. Breast Cancer Res Treat 64 (1): 303

    Google Scholar 

  • Waldeyer W (1872) Die Entwicklung der Carcinome. Virchows Arch Path Anat 55: 67–159

    Google Scholar 

  • Yu Q, Geng Y, Sicinski P (2001) Specific protection against bre- ast cancers by cyclin Di ablation. Nature 411: 1017–1021

    Article  PubMed  CAS  Google Scholar 

  • Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCAI or BRCA2 mutations and sporadic cases. Lancet 349 (9064): 1505–1510

    Article  Google Scholar 

  • Cuzick J (1998) Continuation of the International Breast Cancer Intervention Study (IBIS). Eur J Cancer 34 (11): 1647–1648

    PubMed  CAS  Google Scholar 

  • Cummings SR, Eckert S, Krueger KA, Grady D et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281 (23): 2189–2197

    Article  PubMed  CAS  Google Scholar 

  • Fisher B, Costantino JP, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (18): 1371–1388

    Article  PubMed  CAS  Google Scholar 

  • Ford D, Easton DF, Stratton M et al. (1999) Genetic heterogeneity and penetrance analysis of the BRCAI and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (3): 676–689

    Article  Google Scholar 

  • Hartmann LC, Schaid DJ, Woods JE et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 (2): 77–84

    Article  PubMed  CAS  Google Scholar 

  • Jernstrom H, Lerman C, Ghadirian P et al. (1999) Pregnancy and risk of early breast cancer in carriers of BRCAI and BRCA2. Lancet 354 (9193): 1846–1850

    Article  PubMed  CAS  Google Scholar 

  • National Institutes of Health Consensus Development Statement (1997) Breast Cancer Screening for women ages 40–49.

    Google Scholar 

  • Osin P, Gusterson BA, Philp E, Waller J, Bartek J, Peto J, Crook T (1998) Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 34 (11): 1683–1686

    Article  PubMed  CAS  Google Scholar 

  • Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 (9122): 98–101

    Article  PubMed  CAS  Google Scholar 

  • Rebbeck TR, Levin AM, Eisen A et al. (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCAI mutation carriers. J Natl Cancer Inst 91 (17): 1475–1459

    Article  PubMed  CAS  Google Scholar 

  • Smart CR, Hendrick RE, Rutledge III JH, Smith RA (1997) Benefit of Mammography Screening in Women Ages 40–49; Current Evidences from Randomized Controlled Trials. In: NIH Consensus Development Conference. Breast Cancer Screening for Women Ages 40–49. Abstract book: 83–90

    Google Scholar 

  • Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P (1998) Prevention of breast cancer with tmoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352 (9122): 93–97

    Article  PubMed  CAS  Google Scholar 

  • Minckwitz G, Kaufmann M (1997) Mammographie-Screening für Frauen zwischen 4o and 49. Dtsch Ärzteblatt 94 A: 1436–1438

    Google Scholar 

  • Davidson N, O’Neill A, Vukov A, Osborne CK, Martino S, White D, Abeloff MD for ECOG, SWOG, and CALGB (1999) Effect of chemohormonal therapy in premenopausal, node+, receptor+ breast cancer. An Eastern Cooperative Oncology Group Phase III Intergroup trial (E51288, INT-oio1). Proc ASCO 18: 67a

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348: 1189–1196

    Article  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1998b) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467

    Article  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (1998b) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930–942

    Article  Google Scholar 

  • Fisher B, Brown A, Mamounas E et al. (1997) Effect of Preoperative Chemotherapy on Local-Regional Disease in Women With Operable Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Onco115: 2483–2493

    Google Scholar 

  • Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS (1989) Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7 (1): 36–44

    PubMed  CAS  Google Scholar 

  • Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19 (18): 3817–3827

    PubMed  CAS  Google Scholar 

  • Henderson IC, Berry D, Demetri G et al. for CALGB, ECOG, SWOG, and NCCTG (1998) Improved disease-free and overall survival from the addition of sequential Paclitaxel but not from the escalation of Doxorubicin dose level in the adjuvant chemotherapy of patients with node positive breast cancer. Proc ASCO 17: 390A

    Google Scholar 

  • Honkoop AH, Wagstaff J, Pinedo HM (1998) Management of stage III breast cancer. Oncology 55: 218–227

    Article  PubMed  CAS  Google Scholar 

  • Houghton J, Baum M, Rutqvist L, Nordensjkold B, Nicolucci A, Sawyer W (2001) The ZIPP trial of adjuvant Zoladex in premenopausal patients with early breast cancer: An update at five years. Proc ASCO 19: 93a

    Google Scholar 

  • Jakesz R, Hausmaninger H, Samonigg H (1999) Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four year results of ABCSG trial 5. Proc ASCO 18: 67a

    Google Scholar 

  • Kaufmann M, Jonat W, Abel U (1993) Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/ cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in woman with node-positive breast cancer. J Clin Oncol 11: 454–46o

    PubMed  CAS  Google Scholar 

  • Kaufmann M, Jonat W, von Minckwitz G (2001) Aktuelle Empfehlungen zur Therapie primärer Mammakarzinome. Dt. Ärzteblatt 98: A-2121-A-2123

    Google Scholar 

  • Kaufmann M, von Minckwitz G (1996) Das primäre Mammakarzinom. Vorschläge und aktuelle Aspekte zur adjuvanten systemischen Therapie. Dt. Ärzteblatt 93: A-755-A-758

    Google Scholar 

  • Kaufmann M, von Minckwitz G (2001) Bericht über die NIH Consensus Development Conference zur adjuvanten Therapie von Mammakarzinomen. Onkologie 24: 190–192

    Article  PubMed  CAS  Google Scholar 

  • Kaufmann M, von Minckwitz G for the German Adjuvant Breast Cancer Study Group (GABG) (2001) The emerging role of hormonal ablation as adjuvant therapy in node+ and node-pre-/perimenopausal patients. The Breast 10 (Suppl 3): 123–129

    Google Scholar 

  • Mamounas EP (2000) Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary nodes. NIH Consensus Development Conference on adjuvant therapy for breast cancer. Bethesda

    Google Scholar 

  • Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, Jackisch C, Kaufmann M (1999) Maximized Reduction of Primary Breast Tumor Size Using Preoperative Chemotherapy with Adriamycin and Docetaxel. J Clin Oncol 17: 1999–2005

    Google Scholar 

  • Minckwitz G, Costa SD, Kaufmann M (1998a) Hochdosis Chemotherapie beim Mammakarzinom. Schlusswort. Dt Ärzteblatt 95: B-674-B-677

    Google Scholar 

  • Minckwitz G, Costa SD, Kaufmann M (1998b) Allgemeine Chemotherapie In: Wulf KH, Schmidt-Mathiesen H (Hrsg) Klinik der Frauenheilkunde und Geburtshilfe. Allgemeine gynäkologische Onkologie, 4. Aufl. München: Urban and Schwarzenberg

    Google Scholar 

  • Biganzoli B, Cufer T, Bruning P et al. (2000) Doxorubicin (A)/Taxol (T) Versus Doxorubicin/Cyclophosphamide (C) as First Line Chemotherapy in Metastatic Breast Cancer (MBC): A Phase III Study. Proc ASCO 19: 282

    Google Scholar 

  • Bloomfield DJ (1998) Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16 (3): 1218–1225

    PubMed  CAS  Google Scholar 

  • Bonneterre J, Thurlimann B, Robertson JF et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Onco118 (22): 3748–3757

    Google Scholar 

  • Buzdar AU, Jonat W, Howell A et al. (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83 (6): 1142–1152

    Article  PubMed  CAS  Google Scholar 

  • Carmichael J (2oo1) UKCCCR trial of epirubicin and cyclophosphamide vs epirubicin and taxol in the first line treatment of women with metastatic breast cancer. Proc ASCO 20: 84

    Google Scholar 

  • Chan S, Noel D, Pintér T et al. (1999) on behalf of the entire 303 study group. Prospective Randomized Trial of Docetaxel versus Doxorubicin in Patients with Metastatic Breast Cancer. J Clin Oncol 17: 2341–2354

    Google Scholar 

  • Clemons M, Hamilton T, Goss P (2001) Does treatment at the time of locoregional failure of breast cancer alter prognosis? Cancer Treat Rev 27 (2): 83–97

    Article  PubMed  CAS  Google Scholar 

  • Dalberg K, Mattsson A, Sandelin K, Rutqvist LE (1998) Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer. Breast Cancer Res Treat 49 (1): 69–78

    Article  PubMed  CAS  Google Scholar 

  • Dirix L, Piccart M, Lohrisch C et al. (2001) Efficacy of and tolerance to exemestane versus tamoxifen in 151 line hormone therapy of postmenopausal metastatic breast cancer patients: A European Organisation for the Research and Treatment of Cancer ( EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc ASCO 20: 114

    Google Scholar 

  • Dombernowsky P, Smith I, Falkson G et al. (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16 (2): 453–461

    PubMed  CAS  Google Scholar 

  • Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomisid trials involving 31,510 women. J Clin Onco116: 3439–3460

    Google Scholar 

  • Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339: 974–984

    Article  PubMed  CAS  Google Scholar 

  • Kaufmann M, Henderson IC, Enghofer E (1989) Consensus development in cancer therapy 1. Therapeutic management of metastatic breast cancer. Walter de Gruyter, Berlin, New York

    Google Scholar 

  • Kaufmann M, Jonat W, Kleeberg U et al. (1989) Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J Clin Oncol 7: 1113–1119

    Google Scholar 

  • Kaufmann M, von Minckwitz G (1999) Systemische Therapie metastasierter Mammakarzinome. Deutsches Ärzteblatt 96: A-2509-A-2512

    Google Scholar 

  • Kaufmann M, Bajetta E, Dorix LY et al. (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal woman with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol 18: 1399–1411

    Google Scholar 

  • Klijn JG, Blarney RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R (2001) Combined Hormone Agents Trialists’ Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19 (2): 343–353

    PubMed  CAS  Google Scholar 

  • Konecny G, Thomssen C, Pegram M et al. (2001) Here/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. Proc ASCO 20: 88

    Google Scholar 

  • Kretzler A, Molls M (1997) Grundlagen der Radiotherapiebehandlung ossärer Metastasen. In: Böttcher HD et al. (Hrsg) Klinik der Skelettmetastasen-Grundlagen, Diagnostik und Therapie. Zuckschwerdt

    Google Scholar 

  • Lohrisch C, di Leo A, Piccart M (2001) Optimal adjuvant cytotoxic therapy for breast cancer. ASCO Educational Book: 61–70

    Google Scholar 

  • Lück HJ, Thomssen C, Untch M et al. (2000) Multicentric Phase III Study in First Line Treatment of Advanced Metastatic Breast Cancer (ABC). Epirubicin/Paclitaxel (ET) vs Epirubicin/Cyclophosphamide (EC). A Study of the Ago Breast Cancer Group. Proc ASCO 19: 280

    Google Scholar 

  • Nabholtz JM, Buzdar A, Pollak M et al. (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North Arnerican multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18 (22): 3758–3767

    PubMed  CAS  Google Scholar 

  • Nabholtz JM, Falkson G, Campos D et al. (1999) on behalf of the international TAX3o6 study group. A Phase III Trial Comparing Doxorubicin (A) and Docetaxel (T) (AT) to Doxorubicin and Cyclophosphamide ( AC) as First Line Chemotherapy for MBC. Proc ASCO 18: 485

    Google Scholar 

  • Nabholtz JA, Paterson A, Dirix L et al. (2001) A Phase III randomized trial comparing docetaxel, doxorubicin and cyclophosphamide to FAC as first line chemotherapy for patients with metastatic breast cancer. Proc ASCO 20: 83

    Google Scholar 

  • Oberhoff C, Kieback DG, Wurstlein R et al. (2001) Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 24 (3): 256–260

    Article  PubMed  CAS  Google Scholar 

  • Pienkowski T, Fumeleau P, Eiermann W et al. (2001) Taxotere, Cisplatin and Herceptin (TCH) in first line Her positive metastatic breast cancer patients. A phase II pilot study by the Breast Cancer International Research Group. Proc ASCO 20: 2030

    Google Scholar 

  • Sinn HP, Anton HW, Magener A, von Fournier D, Bastert G, Otto HF (1998) Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. Eur J Cancer 34 (5): 646–653

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (11): 783–792

    Article  PubMed  CAS  Google Scholar 

  • Vogel C, Cobleigh M, Tripathy D, Mass R, Murphy M, Stewart SJ (2001) Superior outcomes with herceptin (trastuzumab) in fluorescence in situ hybridisation-selected patients. Proc ASCO 20: 86

    Google Scholar 

  • Voogd AC, Nielsen M, Peterse JL et al. (2001) Danish Breast Cancer Cooperative Group. Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19 (6): 1688–1697

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Kaufmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. von Minckwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. D. Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Gynäkologie und Geburtshilfe, Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, D-60590, Frankfurt, Deutschland

    Manfred Kaufmann

  2. Frauenklinik Markus-Krankenhaus, Wilhelm-Epstein-Str. 2, D-60431, Frankfurt, Deutschland

    Serban D. Costa

  3. Klinikum St. Marien Amberg, Frauenklinik, Mariahilfbergweg 7, D-92211, Amberg, Deutschland

    Anton Scharl

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kaufmann, M., von Minckwitz, G., Costa, S.D. (2003). Mammakarzinom. In: Kaufmann, M., Costa, S.D., Scharl, A. (eds) Die Gynäkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-11496-4_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-11496-4_32

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-11497-1

  • Online ISBN: 978-3-662-11496-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation